Protalix BioTherapeutics (PLX) Misses Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.22 +9.90%
EPS Growth %: +400.0%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +400.0%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of ($0.22), $0.07 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $62.89 million versus the consensus estimate of $6.12 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- JPMorgan Downgrades Anima Holding SA (ANIM3:BZ) to Neutral
- Goldman Sachs Starts Chagee Holdings (CHA) at Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
